Printed from Voxsanity (voxsanity.com.au) — NCT07181109 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are 18 years of age or older and have an established heart or blood vessel disease (such as coronary artery disease, stroke-related artery disease, or peripheral artery disease).
People who are 55 years of age or older and are considered at high risk for heart or blood vessel disease.
People who have been diagnosed with either established heart or blood vessel disease, or who are at high risk of developing it.
People who are already being treated for high blood pressure with at least 2 standard blood pressure medications, where one of those medications must be a type called a thiazide, thiazide-like, or loop diuretic (a water pill).
Who may not be able to join:
People who have a known history of high blood pressure caused by another underlying medical condition (called secondary hypertension).
People who experience dizziness or lightheadedness when standing up due to a drop in blood pressure (symptomatic orthostatic hypotension).
People whose liver enzyme levels (ALT or AST) are more than 3 times higher than the normal range, as shown in a blood test.
People whose total bilirubin level (a liver-related blood marker) is more than 1.5 times higher than the normal range.
People whose blood clotting test result (INR) is above 1.5 (confirm with trial site).
People whose blood potassium level is higher than 4.8 mEq/L.
People whose kidney function, as measured by an eGFR test, is below 30 mL/min/1.73m².
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Medical Director, Alnylam Pharmaceuticals
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07181109
Sponsor: Alnylam Pharmaceuticals
Phase: Phase 3
Status: Recruiting
Condition: Hypertension
Trial contact: 1-877-ALNYLAM
More information: https://clinicaltrials.gov/study/NCT07181109
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are 18 years of age or older and have an established heart or blood vessel disease (such as coronary artery disease, stroke-related artery disease, or peripheral artery disease).
People who are 55 years of age or older and are considered at high risk for heart or blood vessel disease.
People who have been diagnosed with either established heart or blood vessel disease, or who are at high risk of developing it.
People who are already being treated for high blood pressure with at least 2 standard blood pressure medications, where one of those medications must be a type called a thiazide, thiazide-like, or loop diuretic (a water pill).
Who may not be able to join:
People who have a known history of high blood pressure caused by another underlying medical condition (called secondary hypertension).
People who experience dizziness or lightheadedness when standing up due to a drop in blood pressure (symptomatic orthostatic hypotension).
People whose liver enzyme levels (ALT or AST) are more than 3 times higher than the normal range, as shown in a blood test.
People whose total bilirubin level (a liver-related blood marker) is more than 1.5 times higher than the normal range.
People whose blood clotting test result (INR) is above 1.5 (confirm with trial site).
People whose blood potassium level is higher than 4.8 mEq/L.
People whose kidney function, as measured by an eGFR test, is below 30 mL/min/1.73m².
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Alnylam Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
22 September 2025
Est. completion
30 September 2030
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇨🇴 Colombia
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇳 India
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇱 Poland
🇵🇹 Portugal
🇷🇴 Romania
🇷🇸 Serbia
🇸🇰 Slovakia
🇿🇦 South Africa
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
14 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.